Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial
Authors' conclusion
In patients with septic shock, MB initiated within 24 h reduced time to vasopressor discontinuation and increased vasopressor-free days at 28 days. It also reduced length of stay in ICU and hospital without adverse effects.
Study context
- Population
- Patients with septic shock (Sepsis-3 criteria)randomized
- Participants
- 91 patients
- Comparison
- Early adjunctive methylene blue vs placebo
- Methylene blue (MB)n = 45
- Placebon = 46reference
- Primary endpoint
- Time to vasopressor discontinuation
- Follow-up
- 28 days
Methodological detailssingle-centre, placebo-controlled, retrospectively registered
- Single-centre
- Placebo-controlled
- Retrospectively registered
Primary result
As reported in the abstract
P < 0.001
Secondary outcomes
| Outcome | Estimate | P value |
|---|---|---|
| Vasopressor-free days · day 28 | one more day | P = 0.008 |
| ICU LOS | shorter by 1.5 days | P = 0.039 |
| Hospital LOS | shorter by 2.7 days | P = 0.027 |
Days on mechanical ventilator and mortality
- Similar between groups
Safety
- No serious adverse effects related to MB administration
Original publication
Early adjunctive methylene blue in patients with septic shock: a randomized controlled trial. Crit Care. Published 13 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →